- Home
- RGP vs GLSI Comparison
RGP vs GLSI Comparison
Compare RGP & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGP
- GLSI
- Stock Information
- Founded
- RGP 1996
- GLSI 2006
- Country
- RGP United States
- GLSI United States
- Employees
- RGP N/A
- GLSI N/A
- Industry
- RGP Business Services
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- RGP Consumer Discretionary
- GLSI Health Care
- Exchange
- RGP Nasdaq
- GLSI Nasdaq
- Market Cap
- RGP 155.0M
- GLSI 134.6M
- IPO Year
- RGP 2006
- GLSI 2020
- Fundamental
- Price
- RGP $4.72
- GLSI $12.08
- Analyst Decision
- RGP Sell
- GLSI Strong Buy
- Analyst Count
- RGP 1
- GLSI 1
- Target Price
- RGP $5.00
- GLSI $39.00
- AVG Volume (30 Days)
- RGP 338.0K
- GLSI 60.4K
- Earning Date
- RGP 09-30-2025
- GLSI 08-26-2025
- Dividend Yield
- RGP 5.89%
- GLSI N/A
- EPS Growth
- RGP N/A
- GLSI N/A
- EPS
- RGP N/A
- GLSI N/A
- Revenue
- RGP $551,331,000.00
- GLSI N/A
- Revenue This Year
- RGP N/A
- GLSI N/A
- Revenue Next Year
- RGP $20.14
- GLSI N/A
- P/E Ratio
- RGP N/A
- GLSI N/A
- Revenue Growth
- RGP N/A
- GLSI N/A
- 52 Week Low
- RGP $4.44
- GLSI $8.06
- 52 Week High
- RGP $10.45
- GLSI $16.50
- Technical
- Relative Strength Index (RSI)
- RGP 42.85
- GLSI 57.48
- Support Level
- RGP $4.44
- GLSI $11.44
- Resistance Level
- RGP $4.94
- GLSI $12.83
- Average True Range (ATR)
- RGP 0.24
- GLSI 0.68
- MACD
- RGP -0.01
- GLSI -0.01
- Stochastic Oscillator
- RGP 21.37
- GLSI 63.16
About RGP Resources Connection Inc.
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.